Literature DB >> 25265073

Relative contribution of HIV infection, demographics and body mass index to bone mineral density.

Aoife G Cotter1, Caroline A Sabin, Sibongile Simelane, Alan Macken, Eoin Kavanagh, Jennifer J Brady, Geraldine McCarthy, Juliet Compston, Patrick W G Mallon.   

Abstract

INTRODUCTION: Low bone mineral density (BMD) is common in HIV-positive patients, although the role played by HIV infection versus sociodemographic and metabolic factors remains unclear.
METHODS: Understanding the Pathology of Bone Disease in HIV-infected individuals (HIV UPBEAT) is a prospective cohort study, enrolled HIV-positive and HIV-negative participants from similar demographic backgrounds. Dual X-ray absorptiometry at femoral neck, total hip and lumbar spine and blood tests were performed. Associations between BMD and factors of interest were assessed using multivariable linear regression.
RESULTS: A total of 474 participants were recruited. Two hundred and ten were HIV-positive, of whom, 59% were male, 40% African and median (interquartile range) age was 39 (33, 46) years. HIV acquisition risks were heterosexual sex (46.9%), homosexual sex (25.4%) and intravenous drug use (18.7%). Of the HIV-negative participants, 44% were male, 25% were African and median (interquartile range) age was 42 (34-49) years. HIV infection was independently associated with a 0.062 (P < 0.0001), 0.078 (P < 0.0001) and 0.060 g/cm (P =  0.0002) lower BMD at femoral neck, total hip and lumbar spine, respectively, after adjustment for demographic/ lifestyle factors and BMI. After further adjustment for bone biomarkers, HIV remained independently associated with reduced BMD at each site, although effect sizes were reduced. The HIV-positive group had significantly higher bone turnover (all between-group P < 0.0001). Treatment variables and cumulative exposure to antiretroviral therapy were not associated with lower BMD at femoral neck or total hip, but acquisition of HIV infection via intravenous drug use and longer time since HIV diagnosis were independently associated with lower lumbar spine BMD. DISCUSSION: HIV is independently associated with lower BMD, and its effect is likely mediated, in part, by alterations in bone metabolism.

Entities:  

Mesh:

Year:  2014        PMID: 25265073     DOI: 10.1097/QAD.0000000000000353

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  34 in total

1.  Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy.

Authors:  Robert C Kalayjian; Jeffrey M Albert; Serge Cremers; Samir K Gupta; Grace A McComsey; Karin L Klingman; Carl J Fichtenbaum; Todd T Brown; Babafemi O Taiwo
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

Review 2.  Bone health in HIV and hepatitis B or C infections.

Authors:  Emmanuel Biver; Alexandra Calmy; René Rizzoli
Journal:  Ther Adv Musculoskelet Dis       Date:  2016-10-07       Impact factor: 5.346

Review 3.  Bone Disease in HIV: Recommendations for Screening and Management in the Older Patient.

Authors:  Jennifer Hoy
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

4.  Alcohol Consumption and Bone Mineral Density in People with HIV and Substance Use Disorder: A Prospective Cohort Study.

Authors:  Richard Saitz; Aldina Mesic; Alicia S Ventura; Michael R Winter; Timothy C Heeren; Meg M Sullivan; Alexander Y Walley; Gregory J Patts; Seville M Meli; Michael F Holick; Theresa W Kim; Kendall J Bryant; Jeffrey H Samet
Journal:  Alcohol Clin Exp Res       Date:  2018-06-06       Impact factor: 3.455

Review 5.  Vitamin D and bone loss in HIV.

Authors:  Corrilynn O Hileman; Edgar T Overton; Grace A McComsey
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

Review 6.  Tenofovir and bone health.

Authors:  Philip M Grant; Aoife G Cotter
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

7.  Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Authors:  A Carr; B Grund; J Neuhaus; A Schwartz; J I Bernardino; D White; S Badel-Faesen; A Avihingsanon; K Ensrud; J Hoy
Journal:  HIV Med       Date:  2015-04       Impact factor: 3.180

Review 8.  Bone loss in HIV: a contemporary review.

Authors:  Corrilynn O Hileman; Allison Ross Eckard; Grace A McComsey
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-12       Impact factor: 3.243

9.  Brief Report: Macrophage Activation in HIV-Infected Adolescent Males Contributes to Differential Bone Loss by Sex: Adolescent Trials Network Study 021.

Authors:  Alexandra Ruan; Nicole H Tobin; Kathleen Mulligan; Adrienne Rollie; Fan Li; John Sleasman; Grace M Aldrovandi
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-01       Impact factor: 3.731

Review 10.  Does systemic inflammation and immune activation contribute to fracture risk in HIV?

Authors:  Tara McGinty; Paria Mirmonsef; Patrick W G Mallon; Alan L Landay
Journal:  Curr Opin HIV AIDS       Date:  2016-05       Impact factor: 4.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.